DexCom earnings beat by $0.03, revenue topped estimates
SAN DIEGO—Ma Songjiang, President and Director of Gyre Therapeutics, Inc. (NASDAQ:GYRE), recently executed sales of company stock valued at approximately $40,440, according to a recent SEC filing. The transactions were carried out under a pre-established Rule 10b5-1 trading plan. The sales come as the stock has declined over 15% in the past week, though InvestingPro analysis indicates the company remains undervalued relative to its Fair Value.
On March 19, Songjiang sold 2,000 shares of Gyre Therapeutics’ common stock at a weighted average price of $10.13 per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.25. Following this transaction, Songjiang retained ownership of 2,827,018 shares, held indirectly by a spouse. With a market capitalization of $913 million, analysts maintain a Strong Buy rating on the stock with a $20 price target.
A subsequent sale occurred on March 20, involving another 2,000 shares at a weighted average price of $10.09 per share, with prices ranging from $10.03 to $10.20. This transaction reduced Songjiang’s holdings to 2,825,018 shares.
These transactions are part of a trading plan adopted in September 2024, providing a structured approach to stock sales.
In other recent news, Gyre Therapeutics reported fourth-quarter revenue of $27.87 million, a slight increase from $27.1 million in the same quarter the previous year. However, the company provided full-year 2025 revenue guidance that fell short of analyst expectations, projecting between $118 million and $128 million, compared to the anticipated $135.7 million. This guidance reflects an 11.3% to 20.8% growth over 2024. The company’s outlook assumes the commercial launches of two new products, nintedanib and avatrombopag, aimed at expanding its market presence in China. Gyre plans to begin selling these drugs this year, complementing its existing ETUARY franchise. Despite the lower-than-expected guidance, CEO Han Ying expressed confidence in the company’s ability to successfully launch and expand these products. The company concluded 2024 with $51.2 million in cash and investments. These developments indicate a pivotal year ahead for Gyre’s commercial and clinical-stage portfolios.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.